1Seehofer D,Rayes N,Tullius SG,et al.CMV hepatitis after liver transplantation:incidence,clinical course and long-term follow-up[J].Liver Transplant,2002,8 (12):1138-1146.
2Robin P,Russel H,Weisner C,et al.Prophylaxis and treatment of cytomegalovirus infection after solid organ transplantation[J].Clin Immunothrepy,1996,15:13.
3Piiparinen H,Hockerstedt K,Grenhagen R,et al.Comparison of plasma polymersaechain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients[J].Clin Virol,2001,22(1):111-116.
4Mazzulli T,Drew LW,Yen-Lieberman B,et al.Multicenter comparison of the Digene antigenemia assay,and cell culture for detection of cytomegalovirus viremia[J].Clinmicrobiol,1999,37:958 -963.
5Chou S,Marousk G,Guentzel S,et al.Evolution of mutation conferring multidrug resistance during phophylaxis and therapy for cytomegalovirus disease[J].Infect-Dis,1997,176:786-789.
6Rosen HR,Bener KG,Floria KD,et al.Development of ganciclovirus disease in liver transplant recipients[J].Lancet,1997,350:1729-1733.
8Falagas ME,Snydman DR,Runthazer R,et al.Cytomegalovirus immune globulin prophylaxis is associated with increased survival after orthotropic liver transplantation[J].Clin transplant,1997,11:432-437.
9Badley AD,Seaberyg EC,Poraybo MK,et al.Prophylaxis of cytomegalovirus infection in liver transplantation:A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir[J].Tranplantation,1997,64:66-73.
10Rubin R,Kemmerly SA,Conti D,et al.Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acylovir prophylaxis[J].Transpl Infect Dis,2000,2(3):112-117.
4Alderson P, Green S, Higgins JPT, et al. Cochrane Reviewer' s Handbook 4. 2. 2 The Cochrane Library [M]. Chichester, UK: John Wiley& Sons, Ltd, 2004 : 21-43.
5Gavalda J,de Otero J,Murio E,et al. Two grams daily of oral aeyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transpIant reeipients[J]. Transpl Int, 1997,10(6): 462-465.
6Barkhoh L, Lewensohn-Fuchs I, Ericzon BG, et al. High close acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients [J]. Transpl Infect Dis,1999,1(2) : 89-97.
7Saliba F,Eyraud D,Samuel D, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infec- tion and disease in liver transplant recipients[J]. Transplant Proc, 1993,25 (1) : 1444-1445.
8Paya CV,Wilson JA,Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver trans- plant patients: a randomized, placebo-controlled trial [J]. J Infect Dis, 2002,185 (7) : 854-860.
9Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of ef ficacy and safety of oral ganciclovir in the prevention of cyto- megalovirus disease in liver-transplant recipients[J]. Lancet, 1997,350(9093) :1729-1733.
10Rayes N,Seehofer D, Schmidt CA, et al. Prospective random- ized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation[J]. Transplan- tation,2001,72(5) : 881-885.
